Something tells me that Amarin is playing directly into the generics' hands.
I suspect (and this is purely speculation on my part) that the generics are actually expecting Amarin to lower their prices. The generics have zero overhead for each new drug they sell. All they have is COGS. So they could literally sell IPE at cost, and still be OK.
I think they are all playing the long game. They are trying to force Amarin to lower its prices, to the point that they are no longer profitable and start to bleed cash (as well as bleeding cash in Europe). They know Amarin likely can't sell themselves anytime soon, because nobody is going to buy them. Then they wait for positive outcomes from BRAVE (or not), and eventually Amarin gets sold.
By the time all this happens, they are closer and closer to patent expiry anyway.
But as we have said many times, the generics would have been wise to wait a few years, and let Amarin massively expand the U.S. market, and flood the U.S. with marketing and advertising, getting the Vascepa story out there.
It was a huge missed opportunity by the generics. And unfortunately, that backfired on us, as well.
News 
Market Data 
Discover 
